A Decade of the Protein Corona
Abstract
In this Perspective, we reflect on a decade of research on the protein corona and contemplate its broad implications for future science and engineering at the bio-nano interface. Specifically, we focus on the physical origins and time evolution of the protein corona, differences in the nanoparticle-protein entity in in vitro and in vivo environments, the role of stealth polymers to minimize the formation of the protein corona, relevant computational and theoretical developments, and the "biocorona", a concept extrapolated from the field of nanomedicine. We conclude the Perspective by outlining future directions and opportunities concerning the protein corona in the coming decade.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The present model could not fully represent the complexity of biological systems (e.g., lack of plasma proteins or circulating blood cells) that are known to affect NP properties and nanobio interactions.
“Although the present model could not fully represent the complexity of biological systems (e.g., lack of plasma proteins or circulating blood cells) that are known to a ff ect NP properties and nanobio interactions, 70,71”
From Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model (2019) · cites this paper as [70]
These strategies are still limited at conferring targeting specificity because an additional targeting ligand increases the propensity for protein corona formation to mask targeting ability and inhibit the biological effects of nanoparticles.
“these strategies are still limited at conferring targeting specificity since an additional targeting ligand increases the propensity for protein corona formation to mask the targeting ability and inhibit the biological effects of nanoparticles18–24.”
From Cloaking nanoparticles with protein corona shield for targeted drug delivery. (2018) · cites this paper as [23]
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506 · see citing works
Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., et al. (2018) · Nature communications · doi:10.1038/s41467-018-06979-4 · Cited by 409 · see citing works
Xiao, W., Wang, Y., Zhang, H., Liu, Y., Xie, R., He, X., Zhou, Y., Liang, L., & Gao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120888 · Cited by 174 · see citing works
Khalin, I., Heimburger, D., Melnychuk, N., Collot, M., Groschup, B., Hellal, F., Reisch, A., Plesnila, N., & Klymchenko, A. S. (2020) · ACS Nano · doi:10.1021/acsnano.0c01505 · Cited by 82 · see citing works
Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model
Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P. (2019) · ACS Applied Nano Materials · doi:10.1021/acsanm.8b02056 · Cited by 52 · see citing works
Self-citation
- Authors
- Ke, P. C., Lin, S., Parak, W. J., Davis, T. P., & Caruso, F.
- Affiliations
- Monash University (AU)
- Tongji University (CN)
- Universität Hamburg (DE)
- University of Warwick (GB)
- The University of Melbourne (AU)
- Corresponding author
- Davis, Thomas P.
- Caruso, Frank
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-12-05
- Volume
- 11
- Issue
- 12
- Pages
- 11773-11776
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2773580742
- Cited by
- 672
- References
- 1
- Citations by year
- 2026: 63 · 2025: 68 · 2024: 66 · 2023: 84 · 2022: 90 · 2021: 93 · 2020: 102 · 2019: 74 · 2018: 31
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Nano (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (DFG Grant PA 794/25-1)
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (CE140100036)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Surfaces, Coatings and Films › Polymer Surface Interaction Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- protein corona, nanoparticle-protein interactions, nano-bio interface, stealth polymers, biocorona, nanomedicine, nanoparticle surface modification
- MeSH terms
- Humans, Polymers, Proteins, Protein Engineering, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
